Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27333242 | 0.81 | SIRT2 (0.40) | SIRT2ALDH1A1 | |
| SCHEMBL828034 | 0.78 | — | — | |
| SCHEMBL109451 | 0.77 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18459631 | 0.77 | ALDH1A1 (0.55) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL22660187 | 0.76 | TSHR (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23928720 | 0.74 | SIRT2 (0.41) | SIRT2ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL30910235 | 0.74 | POLB (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14405077 | 0.74 | — | — | |
| SCHEMBL31530817 | 0.74 | ALDH1A1 (0.36) | SIRT2SCN3ASCN4AALDH1A1 | |
| SCHEMBL12574880 | 0.74 | ALDH1A1 (0.36) | SIRT2SCN3ASCN4AELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2026-01-20 | — | — | US | disclosed |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12486262-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12383555-B2 | Methods of treating cancers | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240374605-A1 | METHODS OF TREATING CANCER | FOGHORN THERAPEUTICS INC. | 2024-11-14 | — | — | US | disclosed |
| CN-115677689-B | Polysubstituted benzene PD-L1 inhibitor, composition and application thereof | 杭州和正医药有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2024-09-26 | — | — | US | disclosed |
| EP-2149561-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-2097400-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
| CN-1900080-A | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| CN-1829736-A | severe acute respiratory syndrome coronavirus | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| CN-1269822-C | Inhibitors of kruenza protease and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2006-08-16 | — | — | CN | disclosed |
| CN-1688573-A | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| CN-1486320-A | Inhibitors of kruenza protease and other cysteine proteases | ��ķ��ҽ������˾ | 2004-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317717-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | STS, TP53, SQOR | CA12 30/4885CA1 568/4885CA2 857/4885 |
| US-20240374605-A1 | METHODS OF TREATING CANCER | CARM1, SMARCC1, RB1 | CA12 1664/4885CA1 1294/4885CA2 2764/4885 |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | CA12 4657/4885CA1 4180/4885CA2 4352/4885 |
| US-12486262-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | CA12 4343/4885CA1 4780/4885CA2 4715/4885 |
| US-12383555-B2 | Methods of treating cancers | MCL1, BRPF3, VHL | CA12 1320/4885CA1 2056/4885CA2 2186/4885 |
| US-12528792-B2 | Sulfonamide compounds and the use thereof in the treatment of cancer | SLC10A6, SLCO4C1, SLCO2A1 | CA12 31/4885CA1 394/4885CA2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.